Custom-made ILs solubilized high quantities of the poorly water-soluble drugs, danazol and itraconazole, while a danazol self-emulsifying IL formulation gave rise to higher and more prolonged exposure than the crystalline drug and a lipid formulation, respectively.
A range of ionic liquids (ILs) containing a pyridinium cation were synthesised and their biodegradability was evaluated using the CO2 headspace test (ISO 14593). ILs bearing a 1-(2-hydroxyethyl) side chain were prepared from either pyridine or nicotinic acid derivatives. These ILs showed high levels of biodegradation under aerobic conditions and can be classified as ‘readily biodegradable’. In contrast, pyridinium ILs with methyl or ethyl ether side chains showed significantly lower levels of biodegradability in the same test. Biodegradation studies on a range of novel ILs with acetal and carbamate functionalities, as well as thiazolium-based salts, also showed low levels of mineralization.
1 January 2018 in Journal of Pharmaceutical Sciences
The absolute bioavailability of many small molecule kinase inhibitors (smKIs) is low. The reasons for low bioavailability are multifaceted and include constraints due to first pass metabolism and poor absorption. For smKIs where absorption limits oral bioavailability, low aqueous solubility and high lipophilicity, often in combination with high-dose requirements have been implicated in low and variable absorption, food-effects and absorption-related drug-drug interactions. The current study has evaluated whether preparation of smKIs as lipophilic salts/ionic liquids in combination with co-administration with lipid-based formulations is able to enhance absorption for examples of this compound class. Lipophilic (docusate) salt forms of erlotinib, gefitinib, ceritinib and cabozantinib (as example smKIs demonstrating low aqueous solubility and high lipophilicity) were prepared, and isolated as workable powder solids. In each case, the lipophilic salt exhibited high and significantly enhanced solubility in lipidic excipients (>100 mg/g) when compared to the free base or commercial salt form. Isolation as the lipophilic salt facilitated smKI loading in model lipid formulations at high concentration, increased in vitro solubilization at gastric and intestinal pH and in some cases increased oral absorption (~2-fold for cabozantinib formulations in rats). Application of a lipophilic salt approach can therefore facilitate the use of lipid-based formulations for examples of the smKI compound class where low solubility limits absorption and is a risk factor for increased variability due to food-effects.